Big Data, Big Results
APOLLO is using immense amounts of longitudinal clinical and research
data to understand why the disease responds to or resists certain
treatments. Our plan is to make cancer predictable.
In the next two years, APOLLO is scheduled to conduct such analyses in 2,100 patients enrolled in 28 high-priority clinical trials for melanoma, multiple myeloma, glioblastoma, lymphoma, sarcoma, lung, breast, colorectal, pancreas and ovarian cancers, and cancers caused by the human papillomavirus.